
The U.S. Food and Drug Administration on Thursday approved the first drug that could delay the development of type 1 diabetes (T1D). Teplizumab (Tzield) targets the autoimmune issues that drive the disease, rather than its symptoms, making the medication a game changer. “Today’s approval of a first-in-class therapy adds an important new treatment option for… read on > read on >